Erivedge (Vismodegib) Patent Expiration, LOE Window & CMS Spending

Erivedge (Vismodegib) by Roche / Genentech: FDA Orange Book core substance LOE 2028-11-11 (last listed 2028-12-15), 0 AB generics, $136.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN203388 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-11-11
Last Listed Patent or Exclusivity Date2028-12-15
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$136.8M
2024 Medicare Part D Spend$116.8M
2024 Medicaid Spend$20.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.